Johnson & Johnson
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Latest news
All JNJB34.SA news ›What Companies Does Johnson & Johnson Own?
Get step-by-step guidance on investing in Johnson & Johnson stock and learn the ins and outs of this healthcare company. Eli Lilly, Johnson & Johnson, and AbbVie are the largest companies in the healthcare sector. Companies on the front…
Johnson & Johnson talc charge wipes out 96% of quarterly profit
Keith Howard is a financial journalist specializing in stock market analysis and investment strategies. With over 15 years of experience covering equity markets, earnings reports, and market trends, he brings clarity to complex financial…
Johnson & Johnson Just Raised Its Sales Outlook Again. Here's Why the Dividend King Is Still a Buy.
Although Johnson & Johnson's (JNJ +0.90%) third-quarter revenue and earnings both topped analyst estimates and the company even raised its full-year sales guidance, investors panicked over disappointing sales of medical devices. All told,…
Ankur Maitrika Hospital, Johnson & Johnson organise Laparoscopic Surgery training programme
Greater Kashmir Jammu, Oct 17: Ankur Maitrika Hospital, in collaboration with Johnson & Johnson, organised the GALOP Preceptorship Programme in Gynaecological Laparoscopic Surgery, aimed at enhancing surgical skills and promoting advanced…
JNJ Investors with $100,000 in Losses Have Opportunity to Join Johnson & Johnson Fraud Investigation with SBS Law
The National Law Review JNJ Investors with $100,000 in Losses Have Opportunity to Join Johnson & Johnson Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)--$JNJ--Schall, Brown & Schwartz LLP (“SBS”), a national shareholder…
Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
Healthcare remains a cornerstone for long-term investors, but choosing between a pure-play drugmaker and a diversified conglomerate is difficult. Is Bristol-Myers Squibb (BMY -1.35%) or Johnson & Johnson (JNJ +0.90%) the better choice…
Why Johnson & Johnson (JNJ) Stock Dropped 6% Despite an Earnings Beat
Johnson & Johnson (JNJ) stock traded at $246.74 on Tuesday, down $16.99, or 6%. The drop came even after the company beat third-quarter estimates and raised its 2026 outlook. Johnson & Johnson, JNJ Adjusted earnings per share came in at…
Why Johnson & Johnson (JNJ) Shares Tumbled 5.4% After Beating Q3 Expectations
Shares of Johnson & Johnson (JNJ) tumbled 5.39% to close at $249.51 on Tuesday, shedding $14.22 in value despite delivering third-quarter results that exceeded analyst projections. While the pharmaceutical segment demonstrated robust…
Johnson & Johnson Reports Sustained Psoriasis Drug Response
SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) reported that more than 70% of patients receiving its oral psoriasis treatment ICOTYDE maintained clear or almost clear skin through two years in a Phase 3 clinical trial, providing…
Johnson & Johnson: 3 Key Takeaways for Long-Term Investors
On its third quarter of 2026 earnings call, held on Oct. 13, 2026, Johnson & Johnson (JNJ +0.90%) raised its full-year sales outlook after operational revenue grew 6%. Strong pharmaceutical demand helped the healthcare giant absorb legal…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
marketscreener.com27
-
gurufocus.com17
-
fool.com13
-
seekingalpha.com13
-
theglobeandmail.com13
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.